No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 1695.3x · 10Y median 80.6x · 86th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 12
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T19:54:37.802Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Zenas BioPharma, Inc. (ZBIO) stock was $26.85 as of Oct 6, 2026, 3:50 PM EDT, down 3.51% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +27.8%
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments.
Biotechnology · Waltham, MA
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-1.24
Revenue Est.
$1.01M
Last Quarter Results
EPS
$-1.77
vs Estimate
$-0.76
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ZBIO | $1.70B | $26.85 | -3.51% | +27.75% | N/A | N/A | N/A |
| 2XRAY | $1.70B | $8.50 | -0.75% | -34.07% | -30.27% | -16.38% | vs ZBIO |
| 3PSNL | $1.71B | $16.02 | -2.32% | +122.58% | -1.75% | N/A | vs ZBIO |
| 4NTLA | $1.73B | $12.36 | -3.06% | -35.99% | -37.13% | -3.03% | vs ZBIO |
| 5XERS | $1.73B | $10.02 | -1.13% | +23.41% | +33.72% | N/A | vs ZBIO |
| 6ALHC | $1.74B | $8.37 | -1.55% | -48.69% | -12.15% | N/A | vs ZBIO |
forward FY estimate
N/A
$1.00M
vs Estimate
$15.00M
Consensus Rating
Based on 8 analysts
Average Price Target
$47.88
+78.3% upside
Low
$32.00
Current
$26.85
High
$59.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.32 | $-1.24 | $-1.09 | 2 |
| Quarter ending Dec 2026 | $-1.15 | $-1.11 | $-1.04 | 2 |
| Quarter ending Mar 2027 | $-1.40 | $-1.40 | $-1.40 | 1 |
| Quarter ending Jun 2027 | $-1.06 | $-1.06 | $-1.06 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-5.65 | $-5.63 | $-5.60 | 4 |
| FY 2027 | $-5.31 | $-5.06 | $-4.65 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.01M | $1.01M | $1.01M | 2 |
| Quarter ending Dec 2026 | $11.26M | $11.26M | $11.26M | 4 |
| Quarter ending Mar 2027 | $1.59M | $1.59M | $1.59M | 2 |
| Quarter ending Jun 2027 | $37.50M | $37.50M | $37.50M | 2 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $5.41M | $10.38M | $21.21M | 4 |
| FY 2027 | $32.73M | $57.92M | $97.38M | 5 |
